Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Market Cap	11.05B -10.5%
Revenue (ttm)	1.52B +9.6%
Net Income	474.98M +15.7%
EPS	6.79 +15.7%
Shares Out	70.00M
PE Ratio	23.27
Forward PE	20.57
Dividend	4.00 (2.53%)
Ex-Dividend Date	Mar 2, 2026

Volume	17,999
Open	155.40
Previous Close	156.00
Day's Range	155.00 - 157.90
52-Week Range	125.00 - 181.30
Beta	0.28
Analysts	Hold
Price Target	164.24 (+4.02%)
Earnings Date	Jul 23, 2026

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceutica...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Country: Saudi Arabia
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2025, TADAWUL:4015's revenue was 1.50 billion, an increase of 13.82% compared to the previous year's 1.32 billion. Earnings were 463.80 million, an increase of 30.09%.

Analyst Summary

According to 3 analysts, the average rating for 4015 stock is "Hold." The 12-month stock price target is SAR 164.24, which is an increase of 4.02% from the latest price.

Price Target

SAR 164.24

(4.02% upside)

Analyst Consensus: Hold